SANOFI-AVENTIS WITHDRAWS DRONEDARONE EU MARKETING APPLICATION

Sanofi-aventis has withdraw the European application for marketing authorisation of dronedarone, 400 mg film-coated tablets intended for use in the treatment of atrial fibrillation. Pharmabiz (http://pharmabiz.com/article/detnews.asp?articleid=35012§ionid=)